5,293 trials (keyword fallback)
Chronic Myelomonocytic Leukemia-2 · Myelodysplastic Syndrome · Myeloproliferative Neoplasm
Primary: Overall Survival of Patients Over Age 60 With Newly Diagnosed AML/High Risk MDS — 7 participants
Multiple Sclerosis
Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants
Primary Myelofibrosis · MPN-associated Myelofibrosis
Primary: Percentage of Participants Who Achieved RBC-Transfusion Independence — 17.3; 16.7 percentage of participants — p=1.000
Carcinoid Syndrome · Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm
Primary: The Proportion of Patients Who Achieved SUVmax Reduction of 20% or More Between Baseline and Follow up Scan — 0 Proportion of participants
Anemia · Myelodysplastic/Myeloproliferative Neoplasm · Myelofibrosis
Primary: Anemia-response — 8; 6 Participants
Liver Disease
Primary: Number of Participants That Reached Targeted International Normalized Ratio (INR) Within ±0.1 After First Fresh Frozen Plasma (FFP) Transfusion Completed. — 7; 17…
Asthma
Primary: The Pediatric Asthma Quality of Life Questionnaire (PAQOL) — 5.58; 5.93; 6.49 score on a scale — p=.043
Pulmonary Arterial Hypertension · Familial Primary Pulmonary Hypertension · Primary Pulmonary Hypertension
Primary: Plasma Carnitine Concentration — 44 uM
Vitamin B6 Deficiency
Primary: Total Remethylation of Homocysteine — 6.07; 5.63 micromol/(kg x hr) — p=0.20
Knee Osteoarthritis
Primary: Western Ontario and McMaster University's Osteoarthritis Index (WOMAC) — 24.9; 22.4; 26.1; 22.3 score on a scale
Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) of Gemtuzumab Ozogamicin (GO) When Added to GCLAM (Phase 1) — NA; NA Participants
Myelodysplastic Syndromes
Primary: The Number of Patients With Grade 3 or Higher Serious Adverse Events. — 3 Participants
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Rates of Complete Remission and Complete Remission With Incomplete Recovery of Counts — 38; 33; 41; 23 Participants
Acute Leukemia of Ambiguous Lineage · Acute Myeloid Leukemia · Myeloid Neoplasm
Primary: Feasibility Defined as Proportion of Patients Willing to be Randomized to Either Intensive or Non-intensive Induction and Post Remission Chemotherapy — 3; 47 Participants
Chronic Phase Myelofibrosis · Primary Myelofibrosis · Post-essential Thrombocythemia Myelofibrosis
Primary: European Leukemia Net -International Working Group (ELN-IWG) Criteria — 0 Participants